

## Special Issue

# New Insights into Diagnosis and Treatment of Prostate Cancer and Urological Epidemiology

### Message from the Guest Editors

Prostate cancer is the second most commonly diagnosed cancer in men. Patients with localized prostate cancer mostly undergo definitive curative therapy with surgery or radiation, followed by monitoring of prostate-specific antigen (PSA). However, approximately 30% of patients who undergo definitive treatment will have disease relapse. Androgen-deprivation therapy has been the mainstay of treatment for advanced prostate cancer and usually induces disease regression commonly defined by PSA declines, radiographic responses, and clinical improvement. Over time, castration-resistant prostate cancer (CRPC) cells emerge. CRPC is a heterogeneous disease state that ranges from the serologic progression of disease-only with no radiographic or clinical evidence of metastasis to evidence of metastasis and significant debilitating symptoms from disease progression. Therefore, there is an unmet need to identify new reliable markers, new non-invasive diagnostic approaches, new therapeutic targets, and novel drugs with appropriate treatment therapies to delay and/or overcome the development of CRPC, which results in cancer metastasis.

---

### Guest Editors

Prof. Piotr Chłosta

Medical College, Jagiellonian University, Krakow, Poland

Dr. Mikołaj Przydacz

Medical College, Jagiellonian University, Krakow, Poland

---

### Deadline for manuscript submissions

closed (31 August 2021)



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/70682](https://mdpi.com/si/70682)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com/)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).